<DOC>
	<DOCNO>NCT02506361</DOCNO>
	<brief_summary>This prospective、multicenter、non-comparative interventional case series . 800 breast cancer patient already receive chemotherapy prior study enrol group , include 400 patient receive anthracyclines follow taxanes chemotherapy , 400 patient receive regiment contain taxanes . Three tumor tissue slice enrol patient collect TOP2α assay . Meanwhile , 10 year followed-up survey conduct . The relationship TOP2α expression 5- year 10-year disease free survival ( DFS ) overall survival（OS）will identify study .</brief_summary>
	<brief_title>Evaluation Relationship TOP2α Expression Effect Non Dose-dense Chemotherapy Breast Cancer</brief_title>
	<detailed_description>800 breast cancer patient receive chemotherapy prior study enrol group , include 400 patient receive anthracyclines follow taxanes chemotherapy ( Epirubicin 90 mg/m2 d1 , Cyclophosphamide 600mg/m2 d1，21days/cycle , 4 cycle , follow Docetaxel 75mg/m2 , d1 , 21days/cycle , 4 cycle ; paclitaxel：Epirubicin 90 mg/m2 d1 cyclophosphamide 600mg/m2 d1 , 21day/cycle , 4 cycle , follow paclitaxel 80mg/m2 , weekly , 12 wks ) , 400 patient receive regiment contain taxanes ( FEC：5-FU 600mg/m2 d1 , Epirubicin 90mg/m2 d1 , Cyclophosphamide 500mg/m2 d1 , 21day/cycle , 6 cycle ; EC : Epirubicin 90mg/m2 d1 , Cyclophosphamide 500mg/m2 d1,21 day/cycle , 6 cycle ) .The patient enrol group within one month chemotherapy.Three tumor tissue slice enrol patient collect TOP2α assay . Meanwhile , 10 year followed-up survey conduct . The relationship TOP2α expression 5-year 10-year disease free survival ( DFS ) overall survival（OS）will identify study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>For inclusion study , subject must fulfil follow criterion : 1. . Signed date informed consent indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . 2. . Invasive breast cancer confirm histology cytology tumor complete resection . 3. . Patients without remote organ metastasis . 4. . The Ages patient ≥ 18 year ≤70 year . 5. . Patients positive axillary lymph node , negative axillary lymph node plus one condition : Triplenegative breast cancer , HER 2 ( + ) , Ki67≥15 % . 6. . The value aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) , total bilirubin ( TBIL ) , UREA , CREA less 2 time upper limit normal begin aromatase inhibitors（AIs） therapy . 7. . TOP2α available detect primary tumour tissue . 8. . Patients receive regimen anthracyclines follow Taxanes contain Taxanes nondose dense chemotherapy suggest guideline National Comprehensive Cancer Network （NCCN ) 2014 . Any follow regarded criterion exclusion study : 1. . Patients period pregnancy lactation . 2. . Bilateral breast cancer , inflammatory breast cancer carcinoma situ . 3. . Previous receive neoadjuvant therapy , include chemotherapy , radiotherapy endocrinotherapy . 4. . Presence lifethreatening cancer . 5. . Any severe concomitant condition : uncontrolled cardiac disease uncontrolled diabetes mellitus . et al .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>TOP2α</keyword>
	<keyword>anthracyclines</keyword>
	<keyword>taxanes</keyword>
	<keyword>non dose-dense chemotherapy</keyword>
</DOC>